DOP61 Up-regulated Gremlin 1 in fibroblasts from Crohn’s Disease fibrotic strictures: A potential therapeutic target
Animesh Acharjee(Cancer Research UK Clinical Trials Unit), Subrata Ghosh(University College Cork), Sarah Akiror(University of Birmingham), Asma Amamou(Inserm), Gary Reynolds(Institut thématique Immunologie, inflammation, infectiologie et microbiologie), Louisa Jeffery(Institute of Immunology), Giovanni Santacroce(Università Cattolica del Sacro Cuore), Marietta Iacucci(University Hospitals Birmingham NHS Foundation Trust), Davide Zardo(Ospedale San Bortolo), Georgios V. Gkoutos(University Hospitals Birmingham NHS Foundation Trust), Snehali Majumder(APC Microbiome Institute), Uday N. Shivaji(National Institute for Health and Care Research)
Cited by 3
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
|Journal of Crohn s and Colitis|2021|540